Chemomab is a clinical-stage biotech company that specializes in the development of antibodies for the treatment of immune-mediated and fibrotic (scarring of tissue) disorders including orphan indications. Chemomab is initially focusing on the treatment of Primary Sclerosing Cholangitis (“PSC”) – a chronic progressive cholestatic disease of the liver characterized by inflammation and strictures of the biliary tree inside and/or outside the liver.